TOBRAMYCIN AND DEXAMETHASONE
Clinical safety rating: avoid
Other nephrotoxic or ototoxic drugs increase risk of toxicity Monitor peak and trough levels to minimize risk of nephrotoxicity and ototoxicity.
Tobramycin: aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis and causing misreading of mRNA. Dexamethasone: corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and stabilizing lysosomal membranes.
| Metabolism | Tobramycin: minimal metabolism, primarily excreted unchanged by glomerular filtration. Dexamethasone: metabolized primarily in the liver by CYP3A4 to inactive metabolites. |
| Excretion | Tobramycin is eliminated primarily by the kidneys via glomerular filtration, with 80-90% of an absorbed dose excreted unchanged in urine over 24 hours; minor biliary/fecal excretion (<1%). Dexamethasone is metabolized in the liver and excreted in urine (65%) and feces (35%) as metabolites. |
| Half-life | Tobramycin: 2-3 hours in patients with normal renal function; prolonged (24-60 hours) in renal impairment. Dexamethasone: 3-5 hours in adults; prolonged in hepatic impairment. |
| Protein binding | Tobramycin: <10% bound to plasma proteins. Dexamethasone: 70-80% bound to albumin. |
| Volume of Distribution | Tobramycin: 0.2-0.3 L/kg (confined to extracellular fluid); increased Vd in edema, ascites, or burns. Dexamethasone: 0.6-1.0 L/kg (distributes widely). |
| Bioavailability | Ophthalmic suspension: Systemic bioavailability is negligible (topical route, minimal absorption through cornea/conjunctiva). Not administered orally or parenterally for this indication. |
| Onset of Action | Ophthalmic suspension: Onset of anti-inflammatory effect within 24 hours; antibacterial effect within 1-2 hours. Topical (eye): Clinical improvement in signs/symptoms typically within 2-3 days. |
| Duration of Action | Ophthalmic: Dosing every 4-6 hours yields sustained effect; use for 7-10 days typically. Duration varies with infection/inflammation severity. |
1-2 drops of suspension into the conjunctival sac every 4-6 hours; in severe cases, every 2 hours initially, then taper.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No systemic absorption at ophthalmic doses; no adjustment required. |
| Liver impairment | No systemic absorption at ophthalmic doses; no adjustment required. |
| Pediatric use | 1 drop into affected eye(s) every 4-6 hours; not recommended for children <2 years due to potential for adrenal suppression. |
| Geriatric use | No specific dose adjustment; use lowest effective dose for shortest duration due to increased risk of intraocular pressure elevation and cataract formation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other nephrotoxic or ototoxic drugs increase risk of toxicity Monitor peak and trough levels to minimize risk of nephrotoxicity and ototoxicity.
| FDA category | Positive |
| Breastfeeding | Tobramycin: Minimal excretion into breast milk; M/P ratio not established for topical use. Dexamethasone: Excreted in low amounts; M/P ratio approximately 0.5-0.8. Combined product: Likely safe for breastfeeding if used topically/ophthalmically; systemic absorption low. Caution if high doses or prolonged use. |
| Teratogenic Risk |
■ FDA Black Box Warning
No FDA boxed warning for ophthalmic use. Systemic aminoglycosides have boxed warnings for nephrotoxicity, ototoxicity, and neuromuscular blockade but these are not applicable to ophthalmic formulations.
| Common Effects | Nephrotoxicity |
| Serious Effects |
Hypersensitivity to tobramycin, dexamethasone, or any component; epithelial herpes simplex keratitis (dendritic keratitis); varicella; vaccinia; mycobacterial infection; fungal diseases of ocular structures; untreated parasitic infections; narrow-angle glaucoma.
| Precautions | Prolonged use may result in ocular hypertension/glaucoma, cataract formation, secondary infection (including fungal infections), and delayed wound healing. In patients with known or suspected glaucoma, intraocular pressure should be monitored. Cross-sensitivity to other aminoglycosides may occur. |
Loading safety data…
| TOBRAMYCIN AND DEXAMETHASONE: Tobramycin is an aminoglycoside; associated with potential ototoxicity and nephrotoxicity in the fetus, especially in the second and third trimesters. Dexamethasone is a corticosteroid; chronic high doses increase risk of oral clefts (first trimester), intrauterine growth restriction, and adrenal suppression in the newborn. Overall, limited human data; risk cannot be excluded. Use only if clearly needed. |
| Fetal Monitoring | Monitor maternal renal function, hearing, and vestibular toxicity during prolonged systemic use. For ophthalmic use, routine monitoring is not required. In pregnancy, assess fetal growth if high doses or prolonged use of dexamethasone. |
| Fertility Effects | No specific studies on fertility effects of this combination. Tobramycin may impair fertility in males at high systemic doses (spermatotoxic). Dexamethasone may disrupt menstrual cycles and reduce fertility at high doses. Clinically, ophthalmic use is unlikely to impact fertility. |